Publication | Closed Access
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
48
Citations
5
References
2023
Year
HepatologyAtezolizumab Plus BevacizumabDisease EtiologyMedicineImmunologyPathologyImmune Checkpoint InhibitorLiver CancerOncologyRadiation OncologyHepatocellular Carcinoma
| Year | Citations | |
|---|---|---|
Page 1
Page 1